References

Incidence of traumatic brain injury across the full disease spectrum: A population-based medical record review study

10.1097/ede.0b013e318231d535 · 2011 · External reference

Costs of nonfatal traumatic brain injury in the United States, 2016

10.1097/mlr.0000000000001511 · 2021 · External reference

Traumatic brain injury: An overview of epidemiology, pathophysiology, and medical management

10.1016/j.mcna.2019.11.001 · 2020 · External reference

Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research

10.1016/s1474-4422(17)30371-x · 2017 · External reference

Traumatic brain injury

10.1016/s0140-6736(00)02689-1 · 2000 · External reference

Neurosurgical and intensive care management of traumatic brain injury

10.1055/s-0035-1562884 · 2015 · External reference

Paths to successful translation of new therapies for severe traumatic brain injury in the golden age of traumatic brain injury research: A Pittsburgh vision

10.1089/neu.2018.6203 · 2020 · External reference

Traumatic brain injuries

10.1038/nrdp.2016.84 · 2016 · External reference

Role of excitatory amino acid-mediated ionic fluxes in traumatic brain injury

10.1111/j.1750-3639.1995.tb00621.x · 1995 · External reference

Secondary ischemia impairing the restoration of ion homeostasis following traumatic brain injury

10.3171/jns.2005.103.4.0707 · 2005 · External reference

Glutamate and GABA imbalance following traumatic brain injury

10.1007/s11910-015-0545-1 · 2015 · External reference

Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model

10.1111/j.1471-4159.1993.tb07437.x · 1993 · External reference

Traumatic brain injury: Oxidative stress and neuroprotection

10.1089/ars.2012.4981 · 2013 · External reference

Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury

10.1089/089771504772695904 · 2004 · External reference

Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury

10.1523/jneurosci.17-19-07415.1997 · 1997 · External reference

Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury

10.1016/j.expneurol.2009.04.030 · 2009 · External reference

Impaired cerebral mitochondrial function after traumatic brain injury in humans

10.3171/jns.2000.93.5.0815 · 2000 · External reference

Microglial activation in traumatic brain injury

10.3389/fnagi.2017.00208 · 2017 · External reference

Microglia activation as a biomarker for traumatic brain injury

10.3389/fneur.2013.00030 · 2013 · External reference

Traumatic brain injury causes chronic cortical inflammation and neuronal dysfunction mediated by microglia

10.1523/jneurosci.2469-20.2020 · 2021 · External reference

Inflammation after trauma: Microglial activation and traumatic brain injury

10.1002/ana.22455 · 2011 · External reference

ATP mediates rapid microglial response to local brain injury in vivo

10.1038/nn1472 · 2005 · External reference

Long-term intracerebral inflammatory response after traumatic brain injury

10.1016/j.forsciint.2004.06.027 · 2004 · External reference

Activation of NF-κB mediates astrocyte swelling and brain edema in traumatic brain injury

10.1089/neu.2013.3169 · 2014 · External reference

Morphological and functional alterations of astrocytes responding to traumatic brain injury

10.31083/j.jin.2019.02.110 · 2019 · External reference

Microglial depletion with CSF1R inhibitor during chronic phase of experimental traumatic brain injury reduces neurodegeneration and neurological deficits

10.1523/jneurosci.2402-19.2020 · 2020 · External reference

Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain

10.4049/jimmunol.156.11.4363 · 1996 · External reference

Transient post-operative overexpression of CXCR2 on monocytes of traumatic brain injury patients drives monocyte chemotaxis toward cerebrospinal fluid and enhances monocyte-mediated immunogenic cell death of neurons in vitro

10.1186/s12974-022-02535-6 · 2022 · External reference

Nonclassical monocytes mediate secondary injury, neurocognitive outcome, and neutrophil infiltration after traumatic brain injury

10.4049/jimmunol.1700896 · 2017 · External reference

Early monitoring and quantitative evaluation of macrophage infiltration after experimental traumatic brain injury: A magnetic resonance imaging and flow cytometric analysis

10.1016/j.mcn.2016.11.008 · 2017 · External reference

Traumatic brain injury induces macrophage subsets in the brain

10.1002/eji.201243084 · 2013 · External reference

Oxidative burst of circulating neutrophils following traumatic brain injury in human

10.1371/journal.pone.0068963 · 2013 · External reference

Neutrophils and the blood–brain barrier dysfunction after trauma

10.1002/med.20064 · 2007 · External reference

Cellular infiltration in traumatic brain injury

10.1186/s12974-020-02005-x · 2020 · External reference

Microdialysis in the human brain and its potential role in the development and clinical assessment of drugs

10.2174/092986707780831113 · 2007 · External reference

Inflammation in human brain injury: Intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra

10.1089/neu.2007.0295 · 2007 · External reference

The cytokine response to human traumatic brain injury: Temporal profiles and evidence for cerebral parenchymal production

10.1038/jcbfm.2010.142 · 2011 · External reference

Inflammatory neuroprotection following traumatic brain injury

10.1126/science.aaf6260 · 2016 · External reference

Principal component analysis of the cytokine and chemokine response to human traumatic brain injury

10.1371/journal.pone.0039677 · 2012 · External reference

Pro-inflammatory and pro-apoptotic elements of the neuroinflammatory response are activated in traumatic brain injury

10.1007/978-3-211-85578-2_85 · 2009 · External reference

Neutralization of interleukin-1β following diffuse traumatic brain injury in the mouse attenuates the loss of mature oligodendrocytes

10.1089/neu.2018.5660 · 2018 · External reference

Experimental brain injury induces expression of interleukin-1β mRNA in the rat brain

10.1016/0169-328x(94)00287-o · 1995 · External reference

Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury

10.1089/neu.2008.0562 · 2008 · External reference

10.1007/978-3-7091-6837-0_28

10.1007/978-3-7091-6837-0_28 · 1997 · External reference

Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention

10.1016/j.bbi.2012.06.008 · 2012 · External reference

Moderate and severe traumatic brain injury in adults

10.1016/s1474-4422(08)70164-9 · 2008 · External reference

The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)

10.1126/science.272.5262.735 · 1996 · External reference

Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody

10.7554/elife.36217 · 2018 · External reference

A central role for P2X7 receptors in human microglia

10.1186/s12974-018-1353-8 · 2018 · External reference

P2X7 receptors on microglial cells mediate injury to cortical neurons in vitro

10.1002/glia.20379 · 2006 · External reference

Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism

10.1006/mcne.2001.1054 · 2002 · External reference

The P2X7 receptor drives microglial activation and proliferation: A trophic role for P2X7R pore

10.1523/jneurosci.5512-08.2009 · 2009 · External reference

Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer's disease brain are associated with Aβ, tau pathologies and synaptic loss.

10.1186/s13195-025-01916-2 · 2025 · External reference

Inhibition of P2X7 receptors improves outcomes after traumatic brain injury in rats

10.1007/s11302-017-9579-y · 2017 · External reference

Microglia: Scapegoat, saboteur, or something else?

10.1126/science.1227901 · 2013 · External reference

Immunosuppression after traumatic or ischemic CNS damage: It is neuroprotective and illuminates the role of microglial cells

10.1016/j.pneurobio.2007.12.001 · 2008 · External reference

Microglia at center stage: A comprehensive review about the versatile and unique residential macrophages of the central nervous system

10.18632/oncotarget.23106 · 2017 · External reference

Microglia in neuroinflammation and neurodegeneration: From understanding to therapy

10.3389/fnins.2021.742065 · 2021 · External reference

Microglia biology: One century of evolving concepts

10.1016/j.cell.2019.08.053 · 2019 · External reference

The semantics of microglia activation: Neuroinflammation, homeostasis, and stress

10.1186/s12974-021-02309-6 · 2021 · External reference

The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation

10.1016/j.immuni.2018.04.032 · 2018 · External reference

K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter

10.1016/j.immuni.2013.05.016 · 2013 · External reference

The P2X7 receptor: A key player in IL-1 processing and release

10.4049/jimmunol.176.7.3877 · 2006 · External reference

Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain

10.1523/jneurosci.5417-06.2007 · 2007 · External reference

The human P2X7 receptor alters microglial morphology and cytokine secretion following immunomodulation

10.3389/fphar.2023.1148190 · 2023 · External reference

ILr1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages

10.1096/fj.14-267393 · 2015 · External reference

ATP induces the release of IL-1 from LPS-primed cells in vivo

10.4049/jimmunol.154.6.2821 · 1995 · External reference

Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1β and IL-1α from murine macrophages

10.4049/jimmunol.170.6.3029 · 2003 · External reference

Nonclassical IL-1β secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages

10.4049/jimmunol.179.3.1913 · 2007 · External reference

Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP

10.1038/ncomms10555 · 2016 · External reference

P2X7 receptor differentially couples to distinct release pathways for IL-1β in mouse macrophage

10.4049/jimmunol.180.11.7147 · 2008 · External reference

P2X7 receptor activation leads to NLRP3-independent IL-1β release by human macrophages

10.1186/s12964-023-01356-1 · 2023 · External reference

The role of microglial P2X7: Modulation of cell death and cytokine release

10.1186/s12974-017-0904-8 · 2017 · External reference

Temporal interleukin-1β secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms

10.1074/jbc.m109.072793 · 2010 · External reference

In vivo detection of extracellular adenosine triphosphate in a mouse model of traumatic brain injury

10.1089/neu.2020.7226 · 2021 · External reference

P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat

10.1038/sj.jcbfm.9600250 · 2006 · External reference

P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia

10.1016/j.nbd.2011.12.014 · 2012 · External reference

Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus

10.1186/1742-2094-9-69 · 2012 · External reference

Activation of P2X7 promotes cerebral edema and neurological injury after traumatic brain injury in mice

10.1371/journal.pone.0041229 · 2012 · External reference

Involvement of P2X and P2Y receptors in microglial activation in vivo

10.1007/s11302-007-9082-y · 2007 · External reference

Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury

10.1073/pnas.0902531106 · 2009 · External reference

Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567

10.1111/bph.12314 · 2013 · External reference

Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535

10.1016/j.bmcl.2011.04.077 · 2011 · External reference

Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate

10.3899/jrheum.110874 · 2012 · External reference

Recent advances in CNS P2X7 physiology and pharmacology: Focus on neuropsychiatric disorders

10.3389/fphar.2018.00030 · 2018 · External reference

Neuropsychopharmacology of JNJ-55308942: Evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

10.1038/s41386-018-0141-6 · 2018 · External reference

4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: Optimization of pharmacokinetic properties leading to the identification of a clinical candidate

10.1021/acs.jmedchem.7b00408 · 2017 · External reference

Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants

10.1177/0269881118800067 · 2018 · External reference

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

10.1038/s41398-023-02557-5 · 2023 · External reference

Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432

10.1124/jpet.114.218487 · 2014 · External reference

A dipolar cycloaddition reaction to access 6-methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines enables the discovery synthesis and preclinical profiling of a P2X7 antagonist clinical candidate

10.1021/acs.jmedchem.7b01279 · 2018 · External reference

Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial

10.1177/0269881120914206 · 2020 · External reference

Mammalian P2X7 receptor pharmacology: Comparison of recombinant mouse, rat and human P2X7 receptors

10.1111/j.1476-5381.2009.00233.x · 2009 · External reference

Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding

10.1038/sj.bjp.0707196 · 2007 · External reference

Transcriptomic analysis of purified human cortical microglia reveals age-associated changes

10.1038/nn.4597 · 2017 · External reference

An environment-dependent transcriptional network specifies human microglia identity

10.1126/science.aal3222 · 2017 · External reference

Isolation and culture of microglia

10.1002/cpim.70 · 2019 · External reference

Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures

10.1016/j.neuron.2017.04.043 · 2017 · External reference

Microglia change from a reactive to an age-like phenotype with the time in culture

10.3389/fncel.2014.00152 · 2014 · External reference

A concern on comparing ‘apples’ and ‘oranges’ when differences between microglia used in human and rodent studies go far, far beyond simply species: Comment on Smith and Dragunow

10.1016/j.tins.2014.02.004 · 2014 · External reference

Efficient derivation of microglia-like cells from human pluripotent stem cells

10.1038/nm.4189 · 2016 · External reference

iPSC-derived human microglia-like cells to study neurological diseases

10.1016/j.neuron.2017.03.042 · 2017 · External reference

Characterization of human monocyte-derived microglia-like cells

10.1002/glia.20372 · 2006 · External reference

Patient-specific monocyte-derived microglia as a screening tool for neurodegenerative diseases

10.4103/1673-5374.355740 · 2023 · External reference

A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants

10.1126/scitranslmed.aai7635 · 2017 · External reference

Human monocyte-derived microglia-like cell models: A review of the benefits, limitations and recommendations

10.1016/j.bbi.2022.09.015 · 2023 · External reference

Validation of induced microglia-like cells (iMG cells) for future studies of brain diseases

10.3389/fncel.2021.629279 · 2021 · External reference

Direct induction of ramified microglia-like cells from human monocytes: Dynamic microglial dysfunction in Nasu-Hakola disease

10.1038/srep04957 · 2014 · External reference

Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning

10.1038/s41593-018-0334-7 · 2019 · External reference

Transcriptomic and functional analysis of Aβ1–42 oligomer-stimulated human monocyte-derived microglia-like cells

10.1016/j.bbi.2021.12.001 · 2022 · External reference

A robust approach to differentiate human monocyte-derived microglia from peripheral blood mononuclear cells

10.1016/j.xpro.2022.101747 · 2022 · External reference

A novel in vitro human microglia model: Characterization of human monocyte-derived microglia

10.1016/j.jneumeth.2012.05.025 · 2012 · External reference

Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice

10.1096/fj.11-196089 · 2012 · External reference

A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases

10.1517/13543784.2011.578068 · 2011 · External reference

Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn’s disease: A randomized placebo-controlled, double-blind, phase IIa study

2015 · External reference

Targeting the P2X7 receptor in rheumatoid arthritis: Biological rationale for P2X7 antagonism

2014 · External reference

Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

10.1136/annrheumdis-2011-143578 · 2012 · External reference

The evolution of P2X7 antagonists with a focus on CNS indications

10.1016/j.bmcl.2016.06.048 · 2016 · External reference

Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states

10.1038/sj.bjp.0707265 · 2007 · External reference

[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors

10.1016/j.neuropharm.2008.06.012 · 2009 · External reference

Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists

10.1021/acsmedchemlett.5b00089 · 2015 · External reference

Anti-seizure effects of JNJ-54175446 in the intra-amygdala kainic acid model of drug-resistant temporal lobe epilepsy in mice

10.3389/fphar.2023.1308478 · 2024 · External reference

Microglia dynamics in adolescent traumatic brain injury

10.1186/s12974-020-01994-z · 2020 · External reference

Traumatic brain injury results in unique microglial and astrocyte transcriptomes enriched for type I interferon response

10.1186/s12974-021-02197-w · 2021 · External reference

Depression following a traumatic brain injury: Uncovering cytokine dysregulation as a pathogenic mechanism

10.4103/1673-5374.238604 · 2018 · External reference

Microglia research in the 100th year since its discovery

10.1007/s12264-020-00477-8 · 2020 · External reference

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

10.1038/nm.3806 · 2015 · External reference

MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition

10.1038/s41589-019-0277-7 · 2019 · External reference

(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1β and IL-18

10.1124/jpet.106.111344 · 2007 · External reference

Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase

10.1084/jem.174.4.821 · 1991 · External reference

Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment

10.4049/jimmunol.177.12.8315 · 2006 · External reference

Stimulation of toll-like receptor 3 and 4 induces interleukin-1β maturation by caspase-8

10.1084/jem.20071632 · 2008 · External reference

A RIPK3–caspase 8 complex mediates atypical pro-IL-1β processing

10.4049/jimmunol.1402167 · 2015 · External reference

Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation

10.1016/j.immuni.2012.01.012 · 2012 · External reference

P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice

10.7150/thno.97254 · 2025 · External reference

Cerebrospinal fluid and microdialysis cytokines in severe traumatic brain injury: A scoping systematic review

10.3389/fneur.2017.00331 · 2017 · External reference

Brain injury induced by intracerebral injection of interleukin-1beta and tumor necrosis factor-alpha in the neonatal rat

10.1203/01.pdr.0000134249.92944.14 · 2004 · External reference

Interleukin-1 causes CNS inflammatory cytokine expression via endothelia-microglia bi-cellular signaling

10.1016/j.bbi.2019.06.026 · 2019 · External reference

Interleukin-1beta plays a role in the activation of peripheral leukocytes after blood-brain barrier rupture in the course of subarachnoid hemorrhage

10.2174/156720210790820226 · 2010 · External reference

Hypoxia-induced changes in tight junction permeability of brain capillary endothelial cells are associated with IL-1beta and nitric oxide

10.1016/j.nbd.2004.08.001 · 2004 · External reference

Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia

10.1007/7854_2018_88 · 2020 · External reference

Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis

10.1016/j.schres.2014.03.005 · 2014 · External reference

P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis

10.1186/1742-2094-5-33 · 2008 · External reference

P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis

10.3389/fnmol.2020.00093 · 2020 · External reference

Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain

10.1016/j.pain.2005.01.002 · 2005 · External reference

P2X receptors as drug targets

10.1124/mol.112.083758 · 2013 · External reference